| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Feb 2025 | 31 Jan 2025 |
| CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve The un-audited financial results of the Company for the quarter and nine months ended December 31 2024 (both standalone & consolidated) Financial Results along with the Limited Review Report, Press Release and Investor PPT for the quarter ended December 31, 2024 is enclosed (As Per BSE Announcement Dated on: 07/02/2025) | ||
| Board Meeting | 7 Nov 2024 | 30 Oct 2024 |
| CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve Un-audited Financial Results of the Company for the quarter and half-year ended September 30 2024 (both standalone and consolidated) Financial Results for the quarter and half-year ended September 30, 2024 is enclosed (As Per BSE Announcement Dated on 07.11.2024) | ||
| Board Meeting | 7 Aug 2024 | 31 Jul 2024 |
| CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve Quarterly unaudited financials results Recommendation of Final Dividend Convening AGM and Fixing record date The Board has recommended Final Dividend of INR 2.5 per equity shares subject to the approval of shareholders (As Per BSE Announcement Dated on 07.08.2024) | ||
| Board Meeting | 16 May 2024 | 9 May 2024 |
| CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve Annual audited financial results of the Company for the year ended March 31 2024 (both standalone & consolidated) and declaration of Interim Dividend if any for the FY 2023-24 and fixation of record date for determining the eligibility of shareholders. The Board had approved interim dividend for the year ended 31-03-2024. The details of the same is enclosed herewith (As Per BSE Announcement Dated on 16/05/2024) | ||
The drug is the generic alternative of the Vitamin K1 Injection produced by Hospira Inc and is indicated in the treatment of Vitamin K deficiency-related coagulation disorders.
Here are some of the stocks that may see significant price movement today: ICICI Prudential, Caplin Point, Ashoka Buildcon, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
